Skip to main content

Table 3 Subgroup analysis and meta-regression of the association between CD9 expression and disease-free survival in cancer patients

From: Increased CD9 expression predicts favorable prognosis in human cancers: a systematic review and meta-analysis

Subgroup Number of studies Number of patients Pooled HR (95% CI) p value Heterogeneity Meta-regression
I2 (%) p value p value
Cancer type        0.240
 Breast cancer 4 1714 0.73 (0.23–2.27) 0.583 91.1  < 0.001  
 Digestive system cancer 2 450 0.51 (0.25–1.03) 0.059 44.2 0.181  
 Head and neck cancer 2 187 0.37 (0.15–0.92) 0.033 54.8 0.137  
 Leukemia/lymphoma 2 188 0.39 (0.25–0.61)  < 0.001 0.0 0.921  
 Others 1 320 0.28 (0.11–0.71) 0.007  
CD9 detection method        0.792
 Flow cytometry 1 112 0.41 (0.17–0.95) 0.039  
 IHC 9 2638 0.52 (0.30–0.90) 0.020 84.8  < 0.001  
 RT-PCR 1 109 0.30 (0.14–0.63) 0.002  
Publication year        0.033
 After 2005 5 1954 0.81 (0.41–1.62) 0.552 85.2  < 0.001  
 Before 2005 6 905 0.33 (0.24–0.46)  < 0.001 0.0 0.456  
 Race        0.354
 Asian 7 2240 0.58 (0.30–1.12) 0.102 87.4  < 0.001  
 Caucasian 4 619 0.40 (0.27–0.59)  < 0.001 0.0 0.402  
Sample size        0.896
 Fewer than 140 5 444 0.46 (0.23–0.92) 0.028 69.5 0.011  
 More than 140 6 2415 0.49 (0.26–0.94) 0.032 86.0  < 0.001  
  1. CI, confidence interval; HR, hazard ratio; IHC, immunohistochemistry; RT-PCR, reverse transcription-polymerase chain reaction